HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Delivering Opill Sales Within A Month, Launches ‘Energize’ Efficiency Project Immediately

Executive Summary

Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.

You may also be interested in...



Perrigo Partnership Makes Opill Star Player On WNBA's Reproductive Health Advocacy Team

Less than a month into launching sales of first oral contraceptive approved for US OTC sales, Perrigo announces multi-year partnership with WNBA focused on building confidence, strength and health equity for women.

Perrigo Ships Opill To Stores, But Contraceptive Access Advocates Say It Doesn’t Deliver On Price

First US OTC daily oral contraceptive shipped to major retailers and pharmacies and will be available on shelves nationwide and online later in March. Perrigo says pre-orders for Opill are available currently from select online retailers.

Perrigo’s Rx-To-OTC Contraceptive Pill Switch Unanimously Rejected By German Committee

All nine present voting members of Germany's Expert Committee for Prescription rejected Perrigo's application to switch its progestogen-only contraceptive pill (desogestrel 75μg) from Rx to OTC status. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel